Protecting Your Bone Health: Why Semaglutide and Menopause Care Belong Together
5 minute read
Summary
Weight gain is one of the most common and frustrating changes women experience during perimenopause and menopause. More women are turning to medications like semaglutide for help, but may wonder whether losing weight could come at the expense of their bone health.
This concern is understandable. Menopause is already associated with declines in bone density as estrogen levels decrease. For years, clinicians worried that rapid weight loss, including loss via the use of weight loss medications, may increase fracture risk by accelerating bone loss.
A new study recently revealed that GLP-1 medication semaglutide, was associated with fewer fractures than alternative therapies despite greater reductions in weight. This moves the conversation about weight loss therapies during menopause in an exciting new direction for midlife women.
The Weight Loss and Bone Mass Dilemma in Menopause
Bones are living tissues that adapt to the demands placed on them. Everyday movement and healthy weight-bearing activity cause signals to be sent that help bones maintain their strength. When body weight decreases significantly, those signals become smaller in a process known as mechanical unloading.
Estrogen helps to regulate the balance between bone formation and bone demineralization. Declining estrogen levels during the menopause transition can shift that balance toward increased bone resorption. In the past, clinicians worried that any medications producing substantial weight loss during menopause could inadvertently worsen osteopenia or increase fragility fractures in midlife women. Older studies of intentional loss of weight in postmenopausal women appeared to support this concern by demonstrating a reduction in bone mineral density.
The Stanford Study: A Different Picture Emerges
Earlier this year, researchers from Stanford University Medical Center presented a large retrospective cohort study at the Endocrine Society's Annual Meeting (ENDO 2026) examining fracture outcomes among patients treated with semaglutide compared with other weight reduction measures.
The study indicated that semaglutide treatment was associated with approximately 15% fewer fractures than comparator therapies, despite producing greater reductions in body mass index. Investigators reported 794 fractures in the semaglutide group compared with 1,045 fractures in the comparator group. This observational study cannot establish cause and effect, but the findings suggest that greater weight reduction does not necessarily mean that higher fracture risk will occur when semaglutide is used.
How GLP-1 Medications May Influence Bone
The remodeling of bone is carried out through the coordinated activity of two specialized cell types. Osteoblasts build new bone, while osteoclasts break down older bone. Maintaining healthy bone depends on keeping these processes balanced throughout life.
Research has shown that GLP-1 receptors are present on osteoblasts, suggesting these signaling pathways may help bone formation while reducing excessive bone resorption.
Some of the influences of GLP-1s on bones may also be indirect. Significant loss of body mass can improve mobility and make physical activity easier for many people. Scientists are still working to determine how much of the benefit comes from direct effects on bone.
Personalized Midlife Weight Care
Successful management of weight during menopause involves more than choosing the right medication. Alloy's weight care program is designed around the changes that occur during midlife and includes medically supervised options such as compounded semaglutide and compounded tirzepatide.
Compounded Semaglutide
Starting at $70
Treatment plans are individualized based on medical history, menopause symptoms, treatment goals, medication tolerance, and clinical response.
Compounded Tirzepatide vs. Semaglutide
Compounded semaglutide works by activating the GLP-1 receptor, helping regulate appetite, food intake, and glucose metabolism. Compounded tirzepatide activates both GLP-1 and GIP receptors, providing dual-hormone activity through two complementary metabolic pathways.
Compounded Tirzepatide
Starting at $100
GIP receptors are found throughout the body, including bone tissue. Research suggests GIP signaling may help regulate bone remodeling and reduce bone resorption. Although evidence continues to evolve, both medications are intended to improve metabolic health while allowing treatment to be tailored to an individual's clinical needs.
Supporting Bone Health During Weight Loss
The goal of therapy should be to preserve mobility and bone health and not simply to lose body mass.
Resistance and weight-bearing exercise help provide the mechanical loading that supports healthy bones. Maintaining muscle tone is also important for balance and reducing fall risk. Consuming adequate protein helps preserve lean muscle during weight loss, and calcium, vitamin D, and vitamin K2 support normal bone health.
At Alloy, we encourage all patients taking GLP-1 medications, like semaglutide, to make strength training part of their routine. Just two sessions per week that work major muscle groups can help preserve muscle, support bone health, and reduce the risk of bone loss that can occur during weight loss.
The good news? Strength training doesn't have to mean lifting heavy weights or spending hours at the gym. Resistance bands, light dumbbells, bodyweight exercises (like squats or push-ups), or even modified strength exercises at home can all be effective.
Pairing strength training with GLP-1 treatment can help protect your muscles, strengthen your bones, and support healthy aging while you work toward your weight-loss goals.
When to Talk with a Menopause Specialist
Weight gain and bone health are often discussed separately, but both are influenced by the hormonal changes that occur during menopause. Considering them together can provide a more complete picture when making treatment decisions.
A menopause-specialized physician, like all the doctors at Alloy, can help determine whether medical management of weight fits into an individual's overall care plan while also considering other aspects of long-term health.
New research continues to improve our understanding of how GLP-1 medications affect bone health during weight loss. Although many questions remain, current findings provide reassurance that certain therapies may help with managing weight without the degree of concern about bone health once feared.
Frequently Asked Questions
Does significant weight loss from GLP-1 medications like semaglutide increase fracture risk during menopause?
Historically, clinicians worried that significant weight loss during midlife would accelerate bone density loss due to reduced mechanical loading on bones alongside declining estrogen levels. However, a 2026 Stanford study revealed that semaglutide was actually associated with approximately 15% fewer fractures compared to other weight-loss methods. Researchers believe this may be due to GLP-1 receptors located on bone-building osteoblast cells, which help stimulate bone formation while curbing bone breakdown.
How do compounded tirzepatide and semaglutide differ in how they affect bone tissue?
Compounded semaglutide works exclusively through GLP-1 receptor pathways to regulate appetite and glucose metabolism. Compounded tirzepatide provides dual-hormone action by activating both GLP-1 and GIP receptors. Because GIP receptors are present directly in bone tissue, GIP signaling offers a unique potential advantage by actively helping regulate bone remodeling and further limiting bone resorption during weight loss.
What steps can women take to protect bone density while taking GLP-1 weight loss medications?
Combining medical weight loss with twice-weekly strength training—such as bodyweight exercises, light dumbbells, or resistance bands—provides the mechanical load necessary to protect bones and maintain muscle mass. Maintaining sufficient dietary protein and supplementing with bone-supporting nutrients like calcium, vitamin D, and vitamin K2 also plays a vital role in preserving strength, balance, and long-term skeletal health. **SEO Title Tag** GLP-1 Weight Loss & Bone Health in Menopause: Semaglutide & Fracture Risk **Meta Description** Learn how GLP-1 weight loss medications like semaglutide affect bone density during menopause, and discover essential lifestyle strategies to protect bone health.
References:
Noreña J, et al. Association between semaglutide and risk of bone fractures in type 2 diabetes. Presented at: Endocrine Society Annual Meeting (ENDO 2026); June 14, 2026. Abstract ORF34-04.
Su B, Zhang Y, Wang Y, et al. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk: a systematic review and meta-analysis. Acta Diabetol. 2025;62(5):589-606. doi:10.1007/s00592-024-02480-4.
Ensrud KE, Ewing SK, Stone KL, et al. Intentional weight loss and bone loss in older women. J Am Geriatr Soc. 2003;51(12):1740-1747. doi:10.1046/j.1532-5415.2003.51555.x.
Mieczkowska A, Bouvard B, Chappard D, Mabilleau G. Gastric inhibitory polypeptide (GIP) and bone homeostasis. Endocrine. 2023;79(2):211-222. doi:10.1007/s12020-022-03232-2.
Subscribe
Go ahead, you deserve to
feel fantastic
By subscribing you agree to our Terms of Service & Privacy Policy.